July 22, 2024
Nasal Vaccines Market

Nasal Vaccines Market Primed for Growth through Increased Efficacy of Non-Invasive Delivery

The global nasal vaccines market is comprised of vaccines that are administered via the nasal route rather than via injection. These vaccines work by inducing mucosal immunity in the nose and upper respiratory tract where many pathogens initially enter the body. Some key benefits of nasal vaccines include non-invasiveness compared to injections, ability to generate both systemic and mucosal immune responses, and ease of self or mass administration without requiring specialized training. Common nasal vaccines currently target influenza, tuberculosis, and COVID-19.

The global nasal vaccines market is estimated to be valued at US$ 416.8 million in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights

Higher efficacy and acceptance of nasal delivery compared to injectable formulations is expected to drive increased adoption. Nasal vaccines also provide an attractive option for pediatric populations and in mass vaccination campaigns due to reduced need for sterile techniques and medical expertise during administration.

Market Dynamics:
One of the key drivers referred to in the heading, increased efficacy of non-invasive delivery, will continue propelling market growth over the forecast period. Clinical studies have shown nasal vaccines to induce robust mucosal and systemic immune responses comparable or superior to injectable versions for certain diseases. This is because the nasal mucosa contains respiratory antigen-sampling cells needed to initiate mucosal immune defenses. Nasal delivery also avoids potential pain and medical cautions associated with injections while enabling self-administration. Additionally, the non-invasive nature addresses needle phobia and expands target populations to include young children and those afraid of needles. These collective advantages over injections have accelerated development and adoption of nasal vaccines.

Segment Analysis

The nasal vaccines market is segmented by route of administration, type, application, end user and geography. Based on route of administration, the spray segment dominates with around 70% market share owing to the ease of self-administration and non-invasiveness of nasal sprays. By type, the live attenuated vaccines segment has the largest share as these vaccines provide long lasting immunity similar to injectable vaccines but in a non-invasive manner.

PEST Analysis
Political: Immunization programs by governments and international organizations promote uptake of nasal vaccines. Recent regulatory approvals will boost market growth.
Economic: High disease burden of influenza and COVID-19 increases demand for cost-effective vaccination methods. Growing healthcare expenditures support market expansion.
Social: Increasing awareness about benefits of nasal vaccines over injections drives preference. Rise in vaccine hesitancy may hamper market growth.
Technological: Advancements in delivery techniques and vaccine formulations help develop more effective nasal vaccines.

Key Takeaways
The Global Nasal Vaccines Market Size is expected to witness high growth at a CAGR of 8.6% during the forecast period of 2023 to 2030.

Regional analysis:North America currently dominates the market due to supportive regulatory environment and high vaccination rates. However, Asia Pacific is anticipated to grow at the fastest pace attributed to improving access to healthcare and rising disease awareness in developing nations.

Key players: Key players operating in the nasal vaccines market are AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Johnson & Johnson Services, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Altimmune, Inc., BiondVax Pharmaceuticals Ltd., FluGen Inc., Vaxart, Inc., Intravacc, Ennaid Therapeutics, LLC, Gamma Vaccines Pty Ltd. AstraZeneca and GlaxoSmithKline capture a major share due to their extensive influenza vaccine portfolios.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it